Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.

Quanterix Corporation

Quanterix Corporation (QTRX) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $0.26 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 23.19%. A quarter ago, it was expected that this company would post a loss of $0.27 per share when it actually produced a loss of $0.30, delivering a surprise of -11.11%.
Over the last four quarters, the company has surpassed consensus EPS estimates just once.
Quanterix, which belongs to the Zacks Medical - Products industry, posted revenues of $30.33 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 8.99%. This compares to year-ago revenues of $32.07 million. The company has topped consensus revenue estimates three times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Quanterix shares have lost about 50.3% since the beginning of the year versus the S&P 500's decline of -3.8%.
What's Next for Quanterix?
While Quanterix has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Quanterix: unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.38 on $30.83 million in revenues for the coming quarter and -$1.62 on $138.32 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the bottom 33% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the same industry, Medtronic (MDT), is yet to report results for the quarter ended April 2025. The results are expected to be released on May 21.
This medical device company is expected to post quarterly earnings of $1.58 per share in its upcoming report, which represents a year-over-year change of +8.2%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Medtronic's revenues are expected to be $8.81 billion, up 2.6% from the year-ago quarter.
Should You Invest in Quanterix Corporation (QTRX)?
Before you invest in Quanterix Corporation (QTRX), want to know the best stocks to buy for the next 30 days? Check out Zacks Investment Research for our free report on the 7 best stocks to buy.
Zacks Investment Research has been committed to providing investors with tools and independent research since 1978. For more than a quarter century, the Zacks Rank stock-rating system has more than doubled the S&P 500 with an average gain of +24.08% per year. (These returns cover a period from January 1, 1988 through May 6, 2024.)
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Quanterix Corporation (QTRX) : Free Stock Analysis Report
Medtronic PLC (MDT) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Quanterix Corporation (QTRX) Reports Q1 Loss, Tops Revenue Estimates

The following are today's upgrades for Validea's Price/Sales Investor model based on the published strategy of Kenneth Fisher. This value strategy rewards stocks with low P/S ratios, long-term profit growth, strong free cash flow and consistent profit margins.
TUTOR PERINI CORP (TPC) is a small-cap growth stock in the Construction Services industry. The rating according to our strategy based on Kenneth Fisher changed from 50% to 80% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Tutor Perini Corporation is a civil, building and specialty construction company offering diversified general contracting and design-build services to private customers and public agencies throughout the world. Its Civil segment specializes in public works construction and the replacement and reconstruction of infrastructure. The contracting services provided by the Civil segment include construction and rehabilitation of highways, bridges, tunnels, mass-transit systems, and others. Its Building segment is engaged in providing services for private and public works customers in several specialized building markets, including hospitality and gaming, transportation, commercial offices, and government facilities, among others. Its Specialty Contractors segment specializes in electrical, mechanical, plumbing, HVAC and fire protection systems for a full range of civil and building construction projects in the industrial, commercial, hospitality and gaming, and mass-transit end markets.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
PRICE/SALES RATIO:
PASS
TOTAL DEBT/EQUITY RATIO:
PASS
PRICE/RESEARCH RATIO:
PASS
PRICE/SALES RATIO:
PASS
LONG-TERM EPS GROWTH RATE:
FAIL
FREE CASH PER SHARE:
PASS
THREE YEAR AVERAGE NET PROFIT MARGIN:
FAIL
Detailed Analysis of TUTOR PERINI CORP
TPC Guru Analysis
TPC Fundamental Analysis
QUANTERIX CORP (QTRX) is a small-cap growth stock in the Scientific & Technical Instr. industry. The rating according to our strategy based on Kenneth Fisher changed from 48% to 60% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Quanterix Corporation is a life sciences company. The Company develops and commercializes ultra-sensitive digital immunoassay platforms that advance life sciences research and diagnostics. Its platforms are based on its proprietary digital Simoa detection technology. Its Simoa bead-based and planar array platforms enable customers to detect protein biomarkers in low concentrations in blood, serum, and other fluids. The Company's Simoa technology is based on traditional enzyme-linked immunosorbent assay (ELISA) technology. Its products include HD-X, SR-X, SP-X, Simoa assays and consumables, Nova Beads, and neurofilament light chain (NfL) antibodies and NfL ELISA kits. It also offers contract research services for customers and laboratory developed test services through its Accelerator Laboratory, which provides customers with access to Simoa technology and supports multiple projects and services, including sample testing, homebrew assay development and custom assay development.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
PRICE/SALES RATIO:
PASS
TOTAL DEBT/EQUITY RATIO:
PASS
PRICE/RESEARCH RATIO:
PASS
PRICE/SALES RATIO:
FAIL
LONG-TERM EPS GROWTH RATE:
FAIL
FREE CASH PER SHARE:
FAIL
THREE YEAR AVERAGE NET PROFIT MARGIN:
FAIL
Detailed Analysis of QUANTERIX CORP
QTRX Guru Analysis
QTRX Fundamental Analysis
NERDY INC (NRDY) is a small-cap growth stock in the Business Services industry. The rating according to our strategy based on Kenneth Fisher changed from 48% to 60% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Nerdy Inc. operates a platform for live online learning. The CompanyGs platform leverages technology, including artificial intelligence, to connect students, users, parents, guardians, and purchasers of all ages to tutors, instructors, subject matter experts, educators, and other professionals. Its comprehensive learning destination provides learning experiences across numerous subjects and multiple formats, including learning memberships, one-on-one instruction, small group tutoring, large format classes, tutor chat, essay review, adaptive assessments, and self-study tools. Its flagship business, Varsity Tutors LLC (Varsity Tutors), is a platform for live online tutoring and classes. Its solutions are available directly to students and consumers, as well as through schools and other institutions. Its offerings include Varsity Tutors for Schools, a product suite that leverages its platform capabilities to offer high dosage tutoring and its online learning solutions to institutions.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
PRICE/SALES RATIO:
PASS
TOTAL DEBT/EQUITY RATIO:
PASS
PRICE/RESEARCH RATIO:
PASS
PRICE/SALES RATIO:
FAIL
LONG-TERM EPS GROWTH RATE:
FAIL
FREE CASH PER SHARE:
FAIL
THREE YEAR AVERAGE NET PROFIT MARGIN:
FAIL
Detailed Analysis of NERDY INC
NRDY Guru Analysis
NRDY Fundamental Analysis
ANIKA THERAPEUTICS INC (ANIK) is a small-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Kenneth Fisher changed from 48% to 60% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Anika Therapeutics, Inc. is engaged in the osteoarthritis pain management and regenerative solutions space focused on early intervention orthopedics. The Company is leveraging its core expertise in hyaluronic acid and implant solutions. It partners with clinicians to provide minimally invasive products that restore active living for people around the world. It is developing, manufacturing and commercializing products on its hyaluronic acid (HA) technology platform. It is focused on spaces within orthopedics, including osteoarthritis pain management and regenerative solutions, and its products are delivered in key sites of care, including ambulatory surgery centers. Its products include OA Pain Management, Regenerative Solutions, and others. The OA Pain Management product family consists of Cingal, Monovisc, Orthovisc, Orthovisc mini and Orthovisc-T. Its Regenerative Solutions include Integrity, Hyalofast, Tactoset and NanoFx.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
PRICE/SALES RATIO:
PASS
TOTAL DEBT/EQUITY RATIO:
PASS
PRICE/RESEARCH RATIO:
PASS
PRICE/SALES RATIO:
FAIL
LONG-TERM EPS GROWTH RATE:
FAIL
FREE CASH PER SHARE:
FAIL
THREE YEAR AVERAGE NET PROFIT MARGIN:
FAIL
Detailed Analysis of ANIKA THERAPEUTICS INC
ANIK Guru Analysis
ANIK Fundamental Analysis
Kenneth Fisher Portfolio
About Kenneth Fisher: The son of Philip Fisher, who is considered the "Father of Growth Investing", Kenneth Fisher is a money manager, bestselling author, and longtime Forbes columnist. The younger Fisher wowed Wall Street in the mid-1980s when his book Super Stocks first popularized the idea of using the price/sales ratio (PSR) as a means of identifying attractive stocks. According to his alma mater, Humboldt State University, Fisher is also one of the world's foremost experts on 19th century logging. Appropriately, Fisher's firm, Fisher Investments, is located in a lush forest preserve in Woodside, California, where the contrarian-minded Fisher says he and his employees can get away from Wall Street groupthink.
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Validea Kenneth Fisher Strategy Daily Upgrade Report - 5/10/2025

The following companies are expected to report earnings after hours on 03/17/2025. Visit our Earnings Calendar for a full list of expected earnings releases.
Belite Bio, Inc (BLTE)is reporting for the quarter ending December 31, 2024. The consensus earnings per share forecast from the 2 analysts that follow the stock is $-0.30. BLTE reported earnings of $-0.25 per share for the same quarter a year ago; representing a a increase of 20.00%.Harrow, Inc. (HROW)is reporting for the quarter ending December 31, 2024. The consensus earnings per share forecast from the 2 analysts that follow the stock is $-0.01. HROW reported earnings of $-0.27 per share for the same quarter a year ago; representing a a decrease of -96.30%.Open Lending Corporation (LPRO)is reporting for the quarter ending December 31, 2024. The consensus earnings per share forecast from the 3 analysts that follow the stock is $0.02. LPRO reported earnings of $-0.04 per share for the same quarter a year ago; representing a a decrease of -150.00%.Hallador Energy Company (HNRG)is reporting for the quarter ending December 31, 2024. The consensus earnings per share forecast from the 1 analyst that follows the stock is $-0.18. HNRG reported earnings of $-0.27 per share for the same quarter a year ago; representing a a decrease of -33.33%.Quanterix Corporation (QTRX)is reporting for the quarter ending December 31, 2024. The consensus earnings per share forecast from the 1 analyst that follows the stock is $-0.27. QTRX reported earnings of $-0.33 per share for the same quarter a year ago; representing a a decrease of -18.18%.DiaMedica Therapeutics Inc. (DMAC)is reporting for the quarter ending December 31, 2024. The consensus earnings per share forecast from the 2 analysts that follow the stock is $-0.17. DMAC reported earnings of $-0.14 per share for the same quarter a year ago; representing a a increase of 21.43%.Sangamo Therapeutics, Inc. (SGMO)is reporting for the quarter ending December 31, 2024. The consensus earnings per share forecast from the 4 analysts that follow the stock is $-0.09. SGMO reported earnings of $-0.34 per share for the same quarter a year ago; representing a a decrease of -73.53%.High Tide Inc. (HITI)is reporting for the quarter ending January 31, 2025. The consensus earnings per share forecast from the 2 analysts that follow the stock is $-0.01. HITI reported earnings of $0 per share for the same quarter a year ago; representing aHyperfine, Inc. (HYPR)is reporting for the quarter ending December 31, 2024. The consensus earnings per share forecast from the 1 analyst that follows the stock is $-0.16. HYPR reported earnings of $-0.15 per share for the same quarter a year ago; representing a a increase of 6.67%.The days to cover, as reported in the 2/28/2025 short interest update, increased 163.02% from previous report on 2/14/2025. FibroGen, Inc (FGEN)is reporting for the quarter ending December 31, 2024. The consensus earnings per share forecast from the 1 analyst that follows the stock is $-0.08. FGEN reported earnings of $-0.57 per share for the same quarter a year ago; representing a a decrease of -85.96%.RF Industries, Ltd. (RFIL)is reporting for the quarter ending January 31, 2025. The consensus earnings per share forecast from the 1 analyst that follows the stock is $0.00. RFIL reported earnings of $-0.08 per share for the same quarter a year ago; representing a a decrease of -100.00%.Altus Power, Inc. (AMPS)is reporting for the quarter ending December 31, 2024. The consensus earnings per share forecast from the 5 analysts that follow the stock is $-0.04. AMPS reported earnings of $-0.04 per share for the same quarter a year ago; representing a
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

After-Hours Earnings Report for March 17, 2025 : BLTE, HROW, LPRO, HNRG, QTRX, DMAC, SGMO, HITI, HYPR, FGEN, RFIL, AMPS

QuantumSi Incorporated QSI is scheduled to report its fourth-quarter 2024 results on March 3, 2025.
Find the latest EPS estimates and surprises on Zacks Earnings Calendar.
The Zacks Consensus Estimate for fourth-quarter revenues is pegged at $1.49 million, suggesting growth of 272.5% from the year-ago quarter’s reported figure.
The consensus mark for loss is pegged at 18 cents per share, unchanged over the past 30 days. QSI reported a loss of 16 cents per share in the year-ago quarter.
Quantum-Si Incorporated Price and EPS Surprise
Quantum-Si Incorporated price-eps-surprise | Quantum-Si Incorporated Quote
QSI earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 19.31%.
Let’s see how things have shaped up prior to this announcement.
Key Factors to Note for QSI Q4 Earnings
QSI's fourth-quarter performance is expected to have benefited from year-end capital spending trends and new product launches.
QSI is poised for a potential sequential increase in revenues in the fourth quarter of 2024. It expects to surpass $1 million in quarterly revenues for the first time, driven by improved commercial execution and year-end capital spending.
In the fourth quarter of 2024, QSI expects an uptick in capital spending as customers tend to deploy remaining budgets before year-end. Given the price point of QSI’s instruments, the company is well-positioned to benefit from this trend.
QSI is on track to release its new library preparation kit and barcoding kit in the fourth quarter of 2024. The library prep kit is expected to reduce sample input, improve compatibility with a wider range of proteins, and increase sample success rates. The barcoding kit should reduce sample prep time and enhance sensitivity, which could attract more customers.
QSI has also been actively engaging with the scientific community, presenting research at major industry conferences, including the Human Proteome Organization World Congress and the American Society of Human Genetics Conference. These efforts raise awareness and credibility for its Platinum platform, potentially leading to greater customer adoption.
QSI Underperformed Sector, Peers
QSI shares have plunged 43.7% in the year-to-date period, underperforming the broader Zacks Computer & Technology sector’s decline of 1.6% and the Zacks Electronics - Semiconductors industry’s decline of 5.9%.
Year-to-Date Performance
Image Source: Zacks Investment Research
QSI has also underperformed its peers, including Agilent Technologies A, Quanterix QTRX, and Seer SEER, which are making strong efforts in advancing proteomics technologies.
A, QTRS and SEER shares have lost 0.1%, 2.6% and 25.8%, respectively, in the year-to-date period.
QSI Trading at a Premium
QuantumSi stock is also not so cheap, as its Value Style Score of F suggests a stretched valuation at this moment.
In terms of the forward 12-month Price/Sales ratio, QSI is trading at 18.61, higher than the Zacks Computer & Technology sector’s 6.28.
Price/Sales (F12M)
Image Source: Zacks Investment Research
Expanding Portfolio to Boost QSI’s Prospect
QSI’s expanding portfolio is expected to have been a tailwind. The company continues to make strides in protein sequencing, reinforcing its leadership in next-generation analytical technologies. This positions QSI for long-term growth by meeting the increasing demand for advanced protein analysis tools.
Building on this momentum, QSI recently announced a preprint from Northwestern University demonstrating how its Next-Generation Protein Sequencing on Platinum and Individual Ion Mass Spectrometry enables complementary analysis of interleukin-6 (IL-6), providing detailed insights into its amino acid sequence, post-translational modifications, and proteoform diversity.
Strengthening its commitment to advancing protein analysis, in January, QSI announced the launch of Platinum Pro, its latest benchtop sequencer designed to set a new standard in protein analysis by offering an enlarged touchscreen for a streamlined user experience, flexible local or cloud-based data analysis, and a Pro Mode for custom application development, making it a versatile solution for proteomics research and biopharmaceutical advancements.
What Should Investors Do With QSI Stock?
QuantumSi anticipates that it will likely not achieve its full-year revenue guidance due to delayed customer purchases and a slower-than-expected sales ramp-up despite expecting sequential revenue growth in the fourth quarter of 2024.
QSI positions itself as an industry leader in proteomics, but competition from established players or new entrants could slow the adoption of its Platinum platform.
Further impacting financial performance, QSI’s gross margin is expected to fluctuate due to the mix of instruments versus consumable sales and the impact of acquisition costs or adjustments to inventory predating Platinum’s commercialization.
The company currently has a Growth Score of F, which means it is not an ideal investment for growth-oriented investors. Its stretched valuation is concerning.
QSI currently carries a Zacks Rank #3 (Hold), suggesting that investors should wait for a better entry point to add the stock. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Agilent Technologies, Inc. (A) : Free Stock Analysis Report
Quanterix Corporation (QTRX) : Free Stock Analysis Report
Seer, Inc. (SEER) : Free Stock Analysis Report
Quantum-Si Incorporated (QSI) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

QuantumSi Set to Report Q4 Earnings: Buy, Sell or Hold the Stock?

Zimmer Biomet (ZBH) came out with quarterly earnings of $2.31 per share, beating the Zacks Consensus Estimate of $2.30 per share. This compares to earnings of $2.20 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 0.43%. A quarter ago, it was expected that this orthopedic device maker would post earnings of $1.75 per share when it actually produced earnings of $1.74, delivering a surprise of -0.57%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
Zimmer, which belongs to the Zacks Medical - Products industry, posted revenues of $2.02 billion for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 0.53%. This compares to year-ago revenues of $1.94 billion. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Zimmer shares have added about 2.5% since the beginning of the year versus the S&P 500's gain of 3.1%.
What's Next for Zimmer?
While Zimmer has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Zimmer: unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $2.03 on $1.97 billion in revenues for the coming quarter and $8.57 on $8.01 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the bottom 44% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, Quanterix Corporation (QTRX), has yet to report results for the quarter ended December 2024.
This company is expected to post quarterly loss of $0.27 per share in its upcoming report, which represents a year-over-year change of +18.2%. The consensus EPS estimate for the quarter has been revised 141.7% lower over the last 30 days to the current level.
Quanterix Corporation's revenues are expected to be $34.87 million, up 10.5% from the year-ago quarter.
Should You Invest in Zimmer Biomet Holdings, Inc. (ZBH)?
Before you invest in Zimmer Biomet Holdings, Inc. (ZBH), want to know the best stocks to buy for the next 30 days? Check out Zacks Investment Research for our free report on the 7 best stocks to buy.
Zacks Investment Research has been committed to providing investors with tools and independent research since 1978. For more than a quarter century, the Zacks Rank stock-rating system has more than doubled the S&P 500 with an average gain of +24.08% per year. (These returns cover a period from January 1, 1988 through May 6, 2024.)
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Zimmer Biomet Holdings, Inc. (ZBH) : Free Stock Analysis Report
Quanterix Corporation (QTRX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Zimmer Biomet (ZBH) Surpasses Q4 Earnings and Revenue Estimates

Cresco Labs Inc. (CRLBF) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to loss of $0.04 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -100%. A quarter ago, it was expected that this company would post a loss of $0.01 per share when it actually produced a loss of $0.16, delivering a surprise of -1,500%.
Over the last four quarters, the company has surpassed consensus EPS estimates just once.
Cresco Labs Inc., which belongs to the Zacks Medical - Products industry, posted revenues of $179.78 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 2.94%. This compares to year-ago revenues of $190.56 million. The company has topped consensus revenue estimates three times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Cresco Labs Inc. Shares have lost about 5.6% since the beginning of the year versus the S&P 500's gain of 25.2%.
What's Next for Cresco Labs Inc.
While Cresco Labs Inc. Has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Cresco Labs Inc. Mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is breakeven on $189.39 million in revenues for the coming quarter and -$0.15 on $743.63 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the top 32% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the same industry, Quanterix Corporation (QTRX), is yet to report results for the quarter ended September 2024. The results are expected to be released on November 12.
This company is expected to post quarterly loss of $0.20 per share in its upcoming report, which represents a year-over-year change of +4.8%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Quanterix Corporation's revenues are expected to be $34.32 million, up 9.6% from the year-ago quarter.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 5 Stocks Set to Double. Click to get this free report
Cresco Labs Inc. (CRLBF) : Free Stock Analysis Report
Quanterix Corporation (QTRX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Cresco Labs Inc. (CRLBF) Reports Q3 Loss, Misses Revenue Estimates

BellRing Brands (BRBR) came out with quarterly earnings of $0.54 per share, beating the Zacks Consensus Estimate of $0.44 per share. This compares to earnings of $0.34 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 22.73%. A quarter ago, it was expected that this nutritional supplements company would post earnings of $0.34 per share when it actually produced earnings of $0.45, delivering a surprise of 32.35%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
BellRing Brands, which belongs to the Zacks Medical - Products industry, posted revenues of $515.4 million for the quarter ended June 2024, surpassing the Zacks Consensus Estimate by 2.34%. This compares to year-ago revenues of $445.9 million. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
BellRing Brands shares have lost about 10.4% since the beginning of the year versus the S&P 500's gain of 12.1%.
What's Next for BellRing Brands?
While BellRing Brands has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for BellRing Brands: unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.48 on $531.4 million in revenues for the coming quarter and $1.80 on $1.96 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the top 40% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Quanterix Corporation (QTRX), another stock in the same industry, has yet to report results for the quarter ended June 2024. The results are expected to be released on August 8.
This company is expected to post quarterly loss of $0.23 per share in its upcoming report, which represents a year-over-year change of -43.8%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Quanterix Corporation's revenues are expected to be $34.19 million, up 10.2% from the year-ago quarter.
Only $1 to See All Zacks' Buys and Sells
We're not kidding.
Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.
Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 228 positions with double- and triple-digit gains in 2023 alone.
See Stocks Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BellRing Brands Inc. (BRBR) : Free Stock Analysis Report
Quanterix Corporation (QTRX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

BellRing Brands (BRBR) Q3 Earnings and Revenues Top Estimates

Quanterix Corporation (QTRX) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.16 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 21.21%. A quarter ago, it was expected that this company would post a loss of $0.28 per share when it actually produced a loss of $0.33, delivering a surprise of -17.86%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
Quanterix, which belongs to the Zacks Medical - Products industry, posted revenues of $32.07 million for the quarter ended March 2024, surpassing the Zacks Consensus Estimate by 1.09%. This compares to year-ago revenues of $28.46 million. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Quanterix shares have lost about 38.6% since the beginning of the year versus the S&P 500's gain of 8.6%.
What's Next for Quanterix?
While Quanterix has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Quanterix: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.28 on $34.86 million in revenues for the coming quarter and -$1.04 on $141.33 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the bottom 44% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, Exagen Inc. (XGN), has yet to report results for the quarter ended March 2024. The results are expected to be released on May 13.
This company is expected to post quarterly loss of $0.40 per share in its upcoming report, which represents a year-over-year change of +9.1%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Exagen Inc.'s revenues are expected to be $13.2 million, up 17.5% from the year-ago quarter.
Where Will Stocks Go…
If Biden Wins? If Trump Wins?
The answers may surprise you.
Since 1950, even after negative midterm years, the market has never had a lower presidential election year. With voters energized and engaged, the market has been almost unrelentingly bullish no matter which party wins!
Now is the time to download Zacks' free Special Report with 5 stocks that offer extreme upside for both Democrats and Republicans…
1. Medical manufacturer has gained +11,000% in the last 15 years.
2. Rental company is absolutely crushing its sector.
3. Energy powerhouse plans to grow its already large dividend by 25%.
4. Aerospace and defense standout just landed a potentially $80 billion contract.
5. Giant Chipmaker is building huge plants in the U.S.
Hurry, Download Special Report FREE >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Teleflex Incorporated TFX has completed its previously announced acquisition of Palette Life Sciences AB. Through the acquisition, TFX's Interventional Urology offering now includes Barrigel — a biodegradable and sculptable rectal spacer.
On Jul 26, Teleflex announced entering into a definitive agreement to acquire Palette. Per the terms of the agreement, TFX acquired Palette for an upfront cash payment of $600 million at closing, with additional consideration of up to $50 million upon the attainment of certain commercial milestones.
Few Words on Palette Life Sciences
The main offering of Palette Life Sciences is Barrigel, a Non-Animal Stabilised Hyaluronic Acid (NASHA) spacer, that is intended to lessen the amount of radiation given to the rectum during prostate cancer radiation therapy while enhancing tumor management and patient quality of life. In all sites of service, Barrigel enables one-step assembly, which is readily shaped and highly visible on transrectal ultrasonography. It is also biodegradable and reversible.
Additionally, the Palette Life Sciences portfolio includes the tissue bulking drugs Deflux and Solesta, which are based on NASHA and intended to treat pediatric vesicoureteral reflux and fecal incontinence, respectively.
Financial Details
Teleflex expects Palette’s net revenues around $56 million in 2023 on a standalone basis. In 2023, the acquisition is estimated to dilute adjusted earnings per share by 25 cents (excluding non-recurring purchase accounting adjustments and other acquisition and integration-related costs).
Image Source: Zacks Investment Research
The transaction is estimated to generate a high-teens to low 20% revenue growth profile in 2024 and to dilute adjusted earnings per share by approximately 35 cents (excluding non-recurring purchase accounting adjustments and other acquisition and integration-related costs). Following that, the deal is expected to be more accretive to adjusted EPS.
Strategic Efforts
The acquisition will broaden Teleflex Interventional Urology's portfolio, which already has the UroLift System, to include NASHA spacer and tissue bulking products that enhance patient outcomes in urology and urogynecology disorders, colorectal conditions and radiation oncology procedures.
Urologists, radiation oncologists and other experts will have access to more cutting-edge technologies through the purchase of Palette Life Sciences, which will enable TFX to integrate this intriguing technology into its Interventional Urology business line and improve patient care.
The buyout is in line with Teleflex's strategy of acquiring assets that accelerate its rate of expansion. The company anticipates that the transaction will immediately increase the adjusted gross margin and, in the near future, improve the adjusted operating margin.
Industry Prospects
Per Market Research Future, the global urology surgical instruments market size was estimated at $10.9 billion in 2022 and is expected to witness a CAGR of 8.1% from 2023 to 2030. The market is witnessing rapid growth due to numerous factors, including the rising geriatric population, the increasing prevalence of urological problems, and diseases like kidney stones, urinary incontinence and prostate cancer.
With urology being a growing market segment showing positive trends, the company expects the acquisition to further its strategic vision and play a role in providing differentiated technology to urologists and related specialties.
In the past six months, shares of TFX have declined 4.3% compared with the industry’s 2.8% decline.
Zacks Rank and Key Picks
Teleflex currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader medical space are DaVita Inc. DVA, Quanterix QTRX and Align Technology ALGN, each carrying a Zacks Rank #2 (Buy) at present.
DaVita has an estimated long-term growth rate of 12.7%. DVA’s earnings surpassed estimates in three of the trailing four quarters and missed once, with an average surprise of 21.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
DaVita has gained 25.5% against the industry’s 8.9% decline over the past year.
Estimates for Quanterix’s 2023 loss per share have remained constant at 97 cents in the past 30 days. Shares of the company have surged 141.5% in the past year against the industry’s fall of 5.6%.
QTRX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 30.39%. In the last reported quarter, it posted an earnings surprise of 55.56%.
Estimates for Align Technology’s 2023 earnings have moved up from $8.77 to $8.78 per share in the past 30 days. Shares of the company have gained 27% in the past year compared with the industry’s rise of 14.3%.
ALGN’s earnings beat estimates in three of the trailing four quarters and missed in one. In the last reported quarter, it posted an earnings surprise of 9.90%.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s credited with a “watershed medical breakthrough” and is developing a bustling pipeline of other projects that could make a world of difference for patients suffering from diseases involving the liver, lungs, and blood. This is a timely investment that you can catch while it emerges from its bear market lows.
It could rival or surpass other recent Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Teleflex (TFX) Advances Urology Portfolio With New Buyout

Oct 11 (Reuters) - Blood tests for Alzheimer's are needed to more widely diagnose the brain-wasting disease and understand its prevalence, but it will be another couple of years before they become an everyday tool, medical experts and company executives say.
Blood testing is initially likely to be used to rule out Alzheimer's, with positive results signaling the need for more advanced diagnostics.
Several Alzheimer's blood tests are in the works – and one is already being sold to consumers – but none have been established as accurate, formally approved by regulators or reimbursed by insurers. Some are being used to help screen participants enrolling in clinical trials of Alzheimer's treatments.
Alzheimer's, which gradually destroys memory and thinking skills, is characterized by changes in the brain including buildup of amyloid beta plaques and tau tangles that result in loss of neurons responsible for transmitting information.
Currently, people who might benefit from Leqembi, the new Alzheimer's drug from Eisai 4523.T and Biogen BIIB.O, need those changes diagnosed through cognitive assessment and a cerebrospinal fluid (CSF) test, which requires an invasive lumbar puncture, or an expensive PET brain scan that may not be reimbursed by health insurers.
Even when covered, CSF and PET testing can be hard to access in some parts of the country.
Researchers have been working for years on blood tests for Alzheimer's that can replicate these diagnostic tools. But there is still debate over which biomarkers, or proteins in the blood, signal the presence of amyloid and tau in the brain.
They also say more work is needed to understand the relationship of such biomarkers with race, underlying medical conditions and other factors.
The need for blood tests has become more pressing since the FDA approved Leqembi in July. It is currently reviewing a similar drug, donanemab, from Eli Lilly LLY.N.
Dr. Sarah Kremen, director of the neurobehavior program at Cedars-Sinai Medical Center in Los Angeles, said amyloid on its own is an unreliable marker for Alzheimer's since many people accumulate brain deposits of the protein as they age, but do not develop dementia.
Blood tests that measure the right combination of biomarkers will eventually become the standard for diagnosing Alzheimer's, she said, "but right now, they are not quite ready for prime time."
NEW COMBINATION TEST ARRIVES
Labcorp LH.N on Wednesday began offering to physicians a blood test it says measures markers for amyloid, tau and neurodegeneration with a list price of $626.
In July, Quest Diagnostics DGX.N launched the first direct-to-consumer blood test for Alzheimer's, which costs $399 and aims to detect abnormal levels of amyloid. Data on its accuracy has not been published.
Cedars and other neurology centers took the unusual step of issuing strongly-worded cautions about such consumer tests for people who do not have risk factors or symptoms of Alzheimer's, saying they are best used in conjunction with medical guidance.
"The blood biomarker is a useful screening tool at first, but additional information is needed," said Eliezer Masliah, director of the National Institute on Aging neuroscience division, part of the U.S. National Institutes of Health.
Eisai has a collaboration with C2N Diagnostics to develop evidence supporting the use of blood-based Alzheimer's testing.
Michael Irizarry, head of clinical research at Eisai's neurology division, said he expects the transition to blood-based Alzheimer's diagnostics to happen over the next two years. "Blood tests are progressing quite rapidly," he said.
C2N, which has published and presented its data at medical conferences, recently began offering a $1,450 updated version of its blood test that measures amyloid and tau.
Eli Lilly is working with Quanterix QRTX.O on an experimental tau biomarker blood test, and has partnered with RocheROG.S to develop a test measuring blood levels of a different tau protein as well as a gene associated with Alzheimer's risk.
Bruce Jordan, an executive with Roche Diagnostics, said the company expects to have results from a large trial and file for U.S. approval of its Elecsys Amyloid Plasma Panel in 2025.
The Alzheimer's Association estimates that 6.7 million Americans have the disease, but acknowledges that the number could be 30% lower if biological testing is used.
Another analysis from RAND found that the U.S. age-adjusted prevalence of dementia fell by a about a third to 8.5% between 2000 and 2016, possibly due to more education, less smoking and better heart health care.
"There is a real possibility that the field changes as real world evidence is collected," said Russ Paulsen, chief operating officer at patient advocacy group UsAgainstAlzheimers.
"When there are widely available, scalable, sensitive and specific blood tests it will be an absolute game changer for Alzheimer's patients."
Keep up with the latest medical breakthroughs and healthcare trends with our newsletter Reuters Health Rounds. Sign up here.
Labcorp launches 3-part blood test for Alzheimer's
(Reporting By Deena Beasley; editing by Caroline Humer and Bill Berkrot)
((deena.beasley@thomsonreuters.com; 213 955 6746; Reuters Messaging: deena.beasley.thomsonreuters.com@reuters.net))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.